A pioneering stem cell trial has been approved that will use induced pluripotent stem cells (iPSCs) to try to treat age-related macular degeneration. Because the cells will be derived from each patient, there is no risk of rejection.

This is the first trial on humans to use iPSCs, though both legitimate and dubious trials and treatments using embryonic stem cells and harvested adult stem cells are becoming more and more common.

Read about the first iPSC trial in this BBC News article.